Karyopharm Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Feb 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)(1) Financial Statements
The financial statements listed below are filed as a part of this Annual Report on Form 10-K.
| Pagenumber | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID 42) | 124 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | 127 |
| Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023 | 128 |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2025, 2024 and 2023 | 129 |
| Consolidated Statements of Stockholders’ Deficit for the years ended December 31, 2025, 2024 and 2023 | 130 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023 | 131 |
| Notes to Consolidated Financial Statements | 132 |
(a)(2) Financial Statement Schedules
All financial schedules have been omitted because the required information is either presented in the consolidated financial statements or the notes thereto or is not applicable or required.
(a)(3) Exhibits
The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K and are incorporated herein.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.